4.975USD+4.85%Mkt Cap: 1.72B USDP/E: —Last update: 2026-06-01
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the trea…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.72B USD
Enterprise Value1.35B USD
Revenue (TTM)143.05M USD
Gross Profit53.60M USD
Net Income (TTM)-204.63M USD
Revenue/Share0.4160 USD
Last Price4.975 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees307
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-79.67
PEG—
EV/EBITDA-9.09
EV/Revenue9.42
P/S11.64
P/B5.20
EPS (TTM)-0.43
EPS (Forward)-0.06
52W Range
1.57042% of range9.750
52W High9.750 USD
52W Low1.570 USD
Profitability
Gross Margin85.22%
Oper. Margin4.66%
EBITDA Margin-103.61%
Profit Margin-325.31%
ROE-66.93%
ROA-34.40%
Growth
Revenue Growth2598.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-173.43M USD
CapEx (TTM)8.35M USD
FCF Margin-69.93%
FCF Yield-5.81%
Net Debt-316.74M USD
Net Debt/EBITDA2.14
Balance Sheet
Debt/Equity0.19
Current Ratio7.44
Quick Ratio7.04
Book Value/Sh0.9190 USD
Cash/Share1.533 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)12.33 USD
Target Range7.000 USD – 20.00 USD
# Analysts9
Ownership
Shares Out.347.20M
Float237.62M
Insiders18.59%
Institutions64.84%
Short Interest
Short Ratio11.7d
Short % Float24.48%
Short % Out.14.79%
Shares Short51.49M
Short (prev mo.)50.30M
Technical
SMA 504.616 (+7.8%)
SMA 2005.172 (-3.8%)
Beta1.52
S&P 52W Chg27.70%
Avg Vol (30d)4.16M
Avg Vol (10d)4.17M
Technical Indicators
RSI (14)52.0
MACD-0.0011
MACD Signal-0.0236
MACD Hist.+0.0225
BB Upper5.107 USD
BB Middle4.660 USD
BB Lower4.213 USD
BB Width19.19%
ATR (14)0.2817 USD
Vol Ratio (20d)0.41x